Dublin, July 28, 2023 (GLOBE NEWSWIRE) -- The "Oligonucleotide Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global oligonucleotide therapy market is witnessing impressive growth, expected to rise from $1.1 billion in 2022 to $1.23 billion in 2023, at a compound annual growth rate (CAGR) of 12.2%. Looking ahead, the market is projected to reach $2.1 billion in 2027, demonstrating a CAGR of 14.2%. This remarkable expansion can be attributed to the rise in cancer cases worldwide, driving demand for precision medicine through oligonucleotide therapy.
The global surge in cancer cases is a significant driving force for the oligonucleotide therapy market. In January 2022, the American Cancer Society predicted approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US alone. Lung, prostate, bowel, and female breast cancer account for 43% of all new cancer cases globally, creating a high demand for oligonucleotide therapy in various medical fields, including infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, and kidney diseases.
While the market shows promise, the low number of drug approvals by the FDA has been a hindrance to its growth. As of January 2020, only 11 drugs were approved for treatment, largely due to the stringent manufacturing and drug efficacy standards set by regulatory bodies. However, developers and providers are investing in research and development to remodel the design of oligonucleotide therapy, aiming to reduce side effects on patients. The advent of new and innovative oligonucleotides enables precision medicine approaches with minimal side effects, offering targeted therapies that address patient-specific sequences responsible for rare diseases.
Collaborations and partnerships are playing a vital role in advancing oligonucleotide therapy. For instance, Evotec SE partnered with Secarna Pharmaceuticals GmbH & Co. KG to address unmet medical needs in immunology and immuno-oncology. Evotec's multimodality platform combined with Secarna's tested antisense oligonucleotide technology has the potential to develop disease-modifying medications in areas with high unmet medical needs.
Leading players in the oligonucleotide therapy market include Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holdings ASA, Sarepta Therapeutics Inc., Jazz Pharmaceuticals, and Bausch & Lomb.
With North America being the largest region in the oligonucleotide therapy market, the report provides comprehensive global market statistics, regional shares, detailed market segments, trends, and opportunities to thrive in the oligonucleotide industry. The research report equips businesses with an in-depth analysis of the current and future scenarios in this rapidly evolving field, allowing for informed decision-making and strategic planning.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2023-2027 |
| Estimated Market Value (USD) in 2023 | $1.23 Billion |
| Forecasted Market Value (USD) by 2027 | $2.1 Billion |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Global |
Key Topics Covered
1. Executive Summary
2. Oligonucleotide Therapy Market Characteristics
3. Oligonucleotide Therapy Market Trends And Strategies
4. Oligonucleotide Therapy Market - Macro Economic Scenario
4.1 COVID-19 Impact On Oligonucleotide Therapy Market
4.2 Ukraine-Russia War Impact On Oligonucleotide Therapy Market
4.3 Impact Of High Inflation On Oligonucleotide Therapy Market
5. Oligonucleotide Therapy Market Size And Growth
5.1. Global Oligonucleotide Therapy Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Oligonucleotide Therapy Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Oligonucleotide Therapy Market Segmentation
6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Antisense Oligonucleotide
- Aptamer
- Other Types
6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Infectious Diseases
- Oncology
- Neurodegenerative Disorders
- Cardiovascular Diseases
- Kidney Diseases
- Other Applications
6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals
- Research Institutes
7. Oligonucleotide Therapy Market Regional And Country Analysis
7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
A selection of companies mentioned in this report includes:
- Alnylam Pharmaceuticals Inc.
- Biogen Inc.
- Dynavax Technologies Corp.
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Miragen Therapeuutics Inc.
- PCI Biotech Holdings ASA
- Sarepta Therapeutics Inc.
- Jazz Pharmaceuticals
- Bausch & Lomb
- Kastle Therapeutics
- Akcea Therapeutics
- Arrowhead Pharmaceuticals Inc.
- GlaxoSmithKline PLC
- SomaGenics Inc.
- Hepion Pharmaceuticals
- Regulus Therapeutics Inc.
- Gelead Sciences, Inc.
- Santaris
- InteRNA Technologies B.V.
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/1xk2hd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
